Magda Marquet

This profile gathers the share dealings of Magda Marquet across 3 companies, led by Immix Biopharma, Inc., Anaptysbio, Inc and Arcturus Therapeutics Holdings Inc. Over a trading history stretching from 15 December 2022 to 15 January 2026, the count stands at 9 filings.

Purchases make up the whole of the open-market record (4 purchases, €83k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 4 option exercises.

The median purchase comes to €22k. On 1 out of 4 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 16 January 2026, the filings show an option exercise worth €247k in Anaptysbio, Inc. The latest purchase dates back some time: it was published 1,136 days ago, on 8 September 2023. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.